02:10 , Dec 8, 2017 |  BC Innovations  |  Targets & Mechanisms

Epiphenomena at ASH

While it’s no surprise that cell therapy research is dominant in hematology, the emergence of epigenetics as an equally large focus at this year’s ASH meeting is more notable, reinforcing the resurgence of a field...
07:00 , Jun 6, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Endocrine/metabolic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine/metabolic disease Diabetes Fatty acid binding protein 4 adipocyte (FABP4) In vitro and mouse studies suggest blocking FABP4 could help treat diabetes. In primary hepatocytes and...
08:00 , Nov 10, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Ovarian cancer Fatty acid binding protein 4 adipocyte (FABP4) Patient tissue and mouse studies suggest inhibiting FABP4 could decrease ovarian cancer metastases. Ovarian cancer frequently...
07:00 , Jun 18, 2007 |  BC Week In Review  |  Clinical News

Bristol-Myers preclinical data

Researchers published in Nature that BMS309403 reduced atherosclerotic lesions in mice by about 50% vs. controls. The compound also significantly increased insulin sensitivity and glucose metabolism vs. controls. BMS309403 inhibits adipocyte fatty-acid binding protein aP2...